In the context where advanced cutaneous squamous cell carcinoma (cSCC) is currently a public health issue due to its increasing incidence and where its management is rapidly evolving, it is essential to characterize and monitor changes in therapeutic strategies for patients requiring systemic treatment with adjuvant/neoadjuvant or curative setting. The overall objective of this study is to describe the long-term, real-life management of patients with cSCC requiring systemic therapy, including their clinical characteristics as well as treatment effectiveness and safety. To achieve this aim, the project is based on the establishment of a French national database of patients with cSCC receiving systemic therapy. This is a non-interventional multicenter study involving approximately 30 centers from the French Cutaneous Oncology Group (GCC), including a retrospective phase (from January 2020 for initiation of first-line systemic therapy) followed by a prospective phase. Time perspective is Retrospective and Prospective
Study Type
OBSERVATIONAL
Enrollment
1,500
Adjuvant Treatment Neoadjuvant Treatment Curative Treatment
CHU Dijon Bourgogne
Amiens, France
NOT_YET_RECRUITINGCentre Hospitalier Régional d'Orléans
Annecy, France
RECRUITINGCHRU Besançon
Besançon, France
RECRUITINGCentre Hospitalier de Blois
Blois, France
RECRUITINGHôpital Avicenne
Bobigny, France
RECRUITINGHôpital Saint André,
Bordeaux, France
RECRUITINGHôpital Ambroise Paré
Boulogne-Billancourt, France
RECRUITINGCHU de Caen
Caen, France
NOT_YET_RECRUITINGCHRU de Tours
Chambray-lès-Tours, France
RECRUITINGCHU Estaing
Clermont-Ferrand, France
RECRUITING...and 19 more locations
Frequency and duration of treatments according to the line therapy and treatment intent (curative, adjuvant, or neoadjuvant), and their evolution over time.
Time frame: Long term follow-up, Average of 5 years, Duration of the project not defined
Description in real-life of treatment effectiveness according to treatment type, including response rate, time to response, progression-free survival, overall survival, duration of response, and the incidence of severe toxicities.
Time frame: Long term follow-up, Average of 5 years, duration of the project not defined
Identification of novel prognostic factors or predictive factors of treatment response and/or toxicity.
Time frame: Long term follow-up, Average of 5 years, duration of the project not defined
Characterization of baseline patient features
including demographics, risk factors, comorbidities, clinical presentation and histopatological characteristics
Time frame: At the moment of Cutaneous Squamous Cell Carcinoma Diagnosis, until Day 1 of therapy line
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.